Efficacy and Safety of Aprepitant in Allogeneic Hematopoietic Stem Cell Transplantation

Mayako Uchida,1 Koji Kato,2 Hiroaki Ikesue,1,* Kimiko Ichinose,3 Hiromi Hiraiwa,3 Asako Sakurai,2 Tsuyoshi Muta,2 Katsuto Takenaka,2 Hiromi Iwasaki,4 Toshihiro Miyamoto,2 Takanori Teshima,4 Motoaki Shiratsuchi,5 Kimitaka Suetsugu,1 Kenichiro Nagata,1 Nobuaki Egashira,1 Koichi Akashi,2 and Ryozo Oishi1

1Department of Pharmacy, Kyushu University Hospital, Fukuoka, Japan; 2Department of Medicine and Biosystemic Science, Kyushu University Graduate School of Medical Sciences, Fukuoka, Japan; 3Unit for Cell therapy and Transplantation, Kyushu University Hospital, Fukuoka, Japan; 4Center for Cellular and Molecular Medicine, Kyushu University Hospital, Fukuoka, Japan; 5Department of Medicine and Bioregulatory Science, Kyushu University Graduate School of Medical Sciences, Fukuoka, Japan

STUDY OBJECTIVE To evaluate the efficacy and safety of aprepitant added to standard antiemetic regimens used in high-dose chemotherapy for allogeneic hematopoietic stem cell transplantation (allo-HSCT).

DESIGN Retrospective medical record review.

SETTING Hematology ward of a university hospital in Japan.

PATIENTS Of 88 patients treated with high-dose chemotherapy followed by allo-HSCT, 46 received aprepitant and granisetron as antiemetic therapy (between April 1, 2010, and December 31, 2011), and 42 received granisetron alone (between April 1, 2008, and March 31, 2010).

INTERVENTIONS Patients in both groups received 3 mg of granisetron intravenously 30 minutes before the administration of anticancer drugs. In the aprepitant group, 125 mg of aprepitant was administered orally 60–90 minutes before the administration of the first moderately to highly emetogenic anticancer drug. On the following days, 80 mg of aprepitant was administered orally every morning. The mean administration duration of aprepitant was 3.3 days (range 3–6 days).

MEASUREMENTS AND MAIN RESULTS The primary objective was to evaluate the percentage of patients who achieved complete response (CR; no vomiting and none to mild nausea). The CR rate in the aprepitant group was significantly higher than that in the control group (48% vs 24%, p=0.02). Multivariate analysis showed that nonprophylactic use of aprepitant was associated with failure to achieve CR (odds ratio [OR] 2.92; 95% confidence interval [CI] 1.13–7.99, p=0.03). The frequency of abdominal pain was lower in the aprepitant group (9% vs 25%, p=0.03). Rates of other frequently observed adverse drug events were similar between groups. There was no significant difference in neutrophil engraftment (median 18 vs 17 days), platelet engraftment (median 32 vs 32 days), the incidence of acute graft-versus-host-disease (63% vs 55%, p=0.52), viral infection (74% vs 67%, p=0.49), or 1-year overall survival (63% vs 62%, p=0.90) between the two groups.

CONCLUSIONS The addition of aprepitant to granisetron increases the antiemetic effect without influencing transplantation-related toxicities in allo-HSCT.

KEY WORDS aprepitant, vomiting, high-dose chemotherapy, allogeneic stem cell transplantation.

(Pharmacotherapy 2013;33(9):893–901) doi: 10.1002/phar.1294
Chemotherapy-induced nausea and vomiting (CINV) is one of the most challenging symptoms associated with cancer treatment. To maintain quality of life and enable patients to complete therapy, it is very important to control CINV with the appropriate use of antiemetics. Dexamethasone in combination with a 5-hydroxytryptamine 3 (5-HT3) receptor antagonist represents the standard of care in CINV associated with high-dose conditioning regimens for hematopoietic stem cell transplantation (HSCT). Although the combination of dexamethasone plus a 5-HT3 receptor antagonist is often used prior to HSCT, vomiting is not controlled in as many as 80–93% of patients. Since the neurokinin-1 receptor antagonist aprepitant was approved, the use of triple combination antiemetic therapy (i.e., dexamethasone, 5-HT3 receptor antagonist, and aprepitant) has resulted in further improvements in the control of CINV in non-HSCT patients with solid tumors who are treated with moderate to highly emetogenic chemotherapy. In addition, aprepitant has been recently reported to prevent CINV associated with high-dose preparative regimens followed by HSCT. However, there is still limited information on the safety and efficacy of aprepitant in the setting of allogeneic HSCT (allo-HSCT). Confounding factors that may lead to overlap of acute and delayed CINV in allo-HSCT include the use of calcineurin inhibitors for the control of graft-versus-host disease (GVHD), antibiotics and antifungal agents for infection prophylaxis, total body irradiation (TBI), and high-dose multiday administration of anticancer drugs. Further, many regimens contain drugs such as cyclophosphamide and busulfan that are metabolized by cytochrome (CYP) 3A4. Aprepitant inhibits CYP 3A4, and concomitant use with CYP3A4 substrates may alter the pharmacokinetic properties of these drugs. Thus there is a need to evaluate the antiemetic efficacy and safety of aprepitant in conditioning regimens for allo-HSCT.

In 2010, our institution began using aprepitant as part of the antiemetic prophylaxis strategy for patients undergoing allo-HSCT. The purpose of this study was to evaluate retrospectively the safety and efficacy of aprepitant in allo-HSCT patients.

Patients and Methods

Patients

This study was conducted in accordance with the Declaration of Helsinki and its amendments, and the protocol was approved by the Ethics Committee of Kyushu University Graduate School and Faculty of Medicine. Eligible patients were 20 years old and older who underwent myeloablative or nonmyeloablative conditioning regimens (Table 1) followed by allo-HSCT for hematologic malignancies at the Department of Hematology, Kyushu University Hospital. Forty-six consecutive patients received aprepitant and granisetron as antiemetic prophylaxis (the aprepitant group) between April 1, 2010, and December 31, 2011. Forty-two consecutive patients received granisetron alone (the control group) between April 1, 2008, and March 31, 2010, before the introduction of aprepitant. All patients were included in the analysis, and none were excluded because of severe toxicity.

Treatments

Intravenous granisetron (3 mg) was started 30 minutes before the administration of anticancer drugs on the first day of preparative regimens prior to allo-HSCT in both groups. Intravenous granisetron was administered every 12 hours while patients received chemotherapy and/or TBI. The aprepitant group received an oral dose of aprepitant (125 mg) 60–90 minutes before the administration of the first moderate to highly emetogenic anticancer regimen. Thereafter, aprepitant (80 mg) was administered in the morning on each chemotherapy day. Aprepitant is approved in Japan for a maximum 5-day course of treatment; therefore, we tailored aprepitant administration schedules to correspond to the severity and duration of CINV associated with each individual conditioning regimen. For example, in the myeloablative busulfan and high-dose cyclophosphamide (BU/CY) regimen, we used aprepitant for 6 days because busulfan (moderate emetic risk) was administered on

*Address for correspondence: Hiroaki Ikesue, Department of Pharmacy, Kyushu University Hospital, 3-1-1 Maidashi, Higashi-ku, Fukuoka 812-8582, Japan; e-mail: ikesue@pharm.med.kyushu-u.ac.jp.
© 2013 The Authors. Pharmacotherapy published by Wiley Periodicals, Inc. on behalf of Pharmacotherapy Publications, Inc.
This is an open access article under the terms of the Creative Commons Attribution-NonCommercial License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited and is not used for commercial purposes.
days −7 to −4, and cyclophosphamide (high emetic risk) was administered on days −3 to −2 (Table 1). Metoclopramide (in most cases) or hydroxyzine was administered for breakthrough nausea or vomiting. Glucocorticoids were not administered for emetic control because most patients were profoundly immunosuppressed and at a greatly increased risk of infection.

For GVHD prophylaxis, either cyclosporine A (1.5 mg/kg IV, every 12 hours) or tacrolimus (0.03 mg/kg/day IV as a continuous infusion) were administered starting on day −1. The target concentrations of cyclosporine A and tacrolimus were 150–200 ng/ml (trough concentration) and 12–15 ng/ml (any timing in a continuous infusion), respectively. The first whole blood concentrations of cyclosporine A and tacrolimus were drawn on day 0. Subsequently, blood concentrations of calcineurin inhibitors were measured almost every day during the early posttransplantation stage. Afterward, dosages of each drug were gradually tapered to achieve lower blood concentrations.

### Data Collection and Assessment

All data were retrospectively collected from the electronic medical record system. The primary end point was overall complete response (CR; no vomiting and none to mild nausea) during the first day of conditioning therapy through 5 days after the end of each conditioning regimen. The average number of days for the conditioning regimens was 6.8 days (range 5–8 days) and 6.6 days (range 5–8 days) in the aprepitant and control groups, respectively.

Secondary end points included the percentage of patients with no vomiting, transplantation-related toxicities, 1-year survival rate, and adverse drug events (ADEs). Nausea and vomiting were graded in four categories: CR, major

### Table 1. Schedules of Conditioning Regimens and Antiemetics

| Regimens            | Dosage and Administrationa |
|---------------------|----------------------------|
| TBI/CY              |                            |
| TBI                 | 2 Gy, twice/day Days −6, −5, −4 |
| Cyclophosphamide    | 60 mg/kg, once/day Days −3, −2 |
| Granisetron         | 3 mg, twice/day Days −6 to −2 |
| Aprepitantb         | Once/day 125 mg on day −3; 80 mg on days −2, −1 |
| BU/CY               |                            |
| Busulfan            | 0.8 mg/kg, every 6 hrs Days −7 to −4 |
| Cyclophosphamide    | 60 mg/kg, once/day Days −3, −2 |
| Granisetron         | 3 mg, twice/day Days −7 to −2 |
| Aprepitantb         | Once/day 125 mg on day −7; 80 mg on days −6 to −2 |
| Flu/BU              |                            |
| Fludarabine         | 30 mg/m², once/day Days −8 to −3 |
| Busulfan            | 0.8 mg/kg, every 6 hrs Days −6 to −3 |
| TBI (for UR donor)  | 2 Gy, once/day Day −1 |
| Granisetron         | 3 mg, twice/day Days −8 to −3, −1 |
| Aprepitantb         | Once/day 125 mg on day −6; 80 mg on days −5 to −3 |
| Flu/BU/2            |                            |
| Fludarabine         | 30 mg/m², once/day Days −8 to −3 |
| Busulfan            | 0.8 mg/kg, every 6 hrs Days −6, −5 |
| TBI (for UR donor)  | 2 Gy, once/day Day −1 |
| Granisetron         | 3 mg, twice/day Days −8 to −3, −1 |
| Aprepitantb         | Once/day 125 mg on day −6; 80 mg on days −5, −4 |
| Flu/CY              |                            |
| Fludarabine         | 25 mg/m², once/day Days −5 to −1 |
| Cyclophosphamide    | 30–60 mg/kg, once/day Days −7, −6 |
| Granisetron         | 3 mg, twice/day Days −7 to −1 |
| Aprepitantb         | Once/day 125 mg on day −7; 80 mg on days −6, −5 |
| Flu/MEL/TBI         |                            |
| Fludarabine         | 25 mg/m², once/day Days −8 to −4 |
| Melphalan           | 40 mg/m², once/day Days −3, −2 |
| TBI                 | 2 Gy, once or twice/day Day −1 |
| Granisetron         | 3 mg, twice/day Days −8 to −1 |
| Aprepitantb         | Once/day 125 mg on day −3; 80 mg on days −2, −1 |

TBI = total body irradiation; CY = cyclophosphamide; BU = busulfan; UR = unrelated donor; Flu = fludarabine; MEL = melphalan.

aHematopoietic stem cell transplantation (HSCT) was performed on day 0.

bPatients in the control group did not receive aprepitant.
response (one to two episodes of vomiting and none to moderate nausea or no vomiting and moderate nausea), minor response (three to five episodes of vomiting and any degree of nausea or zero to two episodes of vomiting and severe nausea), and failure (six or more episodes of vomiting with any degree of nausea). Nausea, vomiting, oral mucositis, and ADEs were monitored twice/day (morning and evening) by nurses. The severity of vomiting, oral mucositis, and other ADEs was classified by the Common Terminology Criteria for Adverse Events (CTCAE) v.4.0.

Nurses prepared paper-based ADE monitoring forms excerpted from the CTCAE and used them for the ADE monitoring. Nurses asked patients to self-rate their nausea on a scale from 1 to 4, with 1 indicating no nausea, 2 (mild nausea), 3 (moderate nausea), and 4 (severe nausea). Responses were entered into the electronic medical record system. Engraftment, acute GVHD, and potential infections were evaluated at least once/day by physicians.

Neutrophil and platelet recovery was defined over 3 consecutive days as an absolute neutrophil count of 500 cells/mm$^3$ and 50,000 platelets/mm$^3$ with no transfusion. Diagnosis and clinical grading of acute GVHD were performed according to established criteria. Overall survival (OS) was defined as time from transplantation to death from any cause. Cyclosporine A and tacrolimus blood concentrations were measured on the day of HSCT and the following 2 days to determine the effect of concomitant aprepitant administration. Calcineurin inhibitor concentrations were expressed as the mean ± SD.

**Statistical Analysis**

We used the $\chi^2$ test or the Fisher exact test to compare categorical data between aprepitant and control groups as appropriate, the Mann-Whitney $U$ test to compare age, severity of nausea and vomiting (CR, major response, minor response and failure), and the severity of mucositis, and the $t$ test for the concentration of calcineurin inhibitors and time required for engraftment. OS was estimated using the Kaplan-Meier method, and the difference between survival curves was compared by the log-rank test.

To identify the factors associated with non-CR, data on patient characteristics were analyzed by the $\chi^2$ test or the Fisher exact test. Variables included for univariate analyses were age (50 years or older or 50 years of age or younger), gender, conditioning regimen (myeloablative or nonmyeloablative), and nonprophylactic use of aprepitant. Factors at the $p<0.25$ level of significance in univariate analyses were evaluated as potential covariates in a stepwise multivariate logistic regression with backward selection. Data were analyzed using JMP v.9.0.0.2 (SAS Institute Inc., Cary NC, USA), and a $p$ value $<0.05$ was considered significant.

**Results**

**Patient Characteristics**

There were no significant differences in gender, median age, or disease between aprepitant and control groups (Table 2). The results are presented as the ratio of the number of patients in each group.

### Table 2. Patient Characteristics

| Characteristics                  | Control (n=42)$^a$ | Aprepitant (n=46)$^b$ | p Value |
|----------------------------------|-------------------|-----------------------|---------|
| Gender (%)                       |                   |                       |         |
| Male                             | 24 (57.1)         | 28 (60.9)             | 0.723   |
| Female                           | 18 (42.9)         | 18 (39.1)             |         |
| Age Median, yr (range)           | 47 (22–68)        | 53 (22–69)            | 0.224   |
| Diagnosis (%)                    |                   |                       |         |
| Acute myeloblastic leukemia      | 17 (40.5)         | 18 (39.1)             |         |
| Acute lymphoblastic leukemia     | 4 (9.5)           | 3 (6.5)               |         |
| Adult T-cell leukemia/lymphoma   | 8 (19.0)          | 6 (13.0)              |         |
| Malignant lymphoma               | 4 (9.5)           | 11 (23.9)             |         |
| Myelodysplastic syndrome         | 5 (11.9)          | 3 (6.5)               |         |
| Other                            | 4 (9.5)           | 5 (10.9)              |         |
| Conditioning regimen (%)         | 22 (52.4)         | 20 (43.5)             | 0.404   |
| Myeloablative regimens           |                   |                       |         |
| TBI/CY                           | 13 (31.0)         | 12 (26.1)             |         |
| BU/CY                            | 4 (9.5)           | 2 (4.3)               |         |
| Flu/BU4                          | 5 (11.9)          | 6 (13.0)              |         |
| Nonmyeloablative regimens        | 20 (47.6)         | 26 (56.5)             |         |
| Flu/BU2                          | 6 (14.3)          | 12 (26.1)             |         |
| Flu/CY                           | 3 (7.1)           | 1 (2.2)               |         |
| Flu/MEL/TBI                      | 11 (26.2)         | 13 (28.3)             |         |
| Sources of stem cells (%)        |                   |                       |         |
| Related donor                    | 16 (38.1)         | 14 (30.4)             | 0.504   |
| PB                               | 10 (23.8)         | 11 (23.9)             |         |
| BM                               | 6 (14.3)          | 3 (6.5)               |         |
| Unrelated donor                  | 26 (61.9)         | 32 (69.6)             |         |
| BM                               | 10 (23.8)         | 23 (50.0)             |         |
| CB                               | 16 (38.1)         | 9 (19.6)              |         |

$^a$Patients in the control group received granisetron alone as an antiemetic.

$^b$Patients in the aprepitant group received aprepitant and granisetron as antiemetics.
and control groups (Table 2). The average number of days of conditioning regimens was 6.8 days (range 5–8 days) and 6.6 days (range 5–8 days) in the aprepitant and control groups, respectively. The average administration duration of aprepitant was 3.3 days (range 3–6 days).

The only exception was in the unrelated bone marrow donor source of stem cells that included 50.0% of patients from the aprepitant group versus 23.8% from the control group. The myeloablative-to-nonmyeloablative conditioning regimen ratio was equivalent for both groups. The ratio of recipients treated by the TBI/non-TBI regimen was also equivalent in the aprepitant group (aprepitant vs control: 60.0% vs 59.1% in the myeloablative conditioning regimen with TBI, \( p = 0.952 \)). For GVHD prophylaxis, cyclosporine A with short-term methotrexate (sMTX) was used for related allo-HSCT (aprepitant vs control: 46.7% vs 53.3%, \( p = 0.449 \)) and tacrolimus with sMTX for unrelated allo-HSCT (aprepitant vs control: 55.2% vs 44.8%, \( p = 0.449 \)).

**Antiemetic Efficacy**

The overall CR rate in the aprepitant group was significantly greater than in the control group (47.8% vs 23.8%, \( p = 0.019 \)) (Figure 1A). The rates of patients who achieved no vomiting (67.4% vs 35.7%, \( p = 0.003 \)) was also significantly greater in the aprepitant group (Figure 1B). The rates of major response, minor response, and failure in the aprepitant group were 39.1%, 8.7%, and 4.3%, respectively, whereas those in the control group were 23.8%, 33.3%, and 19.0%, respectively (\( p = 0.001 \)). The percentage of patients without nausea was not significantly different than controls (10.9% vs 4.8%, \( p = 0.256 \)). However, the percentage of patients with moderate to severe nausea was significantly lower in the aprepitant group (31.0% vs 52.2%, \( p = 0.044 \)).

The antiemetic effect of aprepitant in patients who received the myeloablative versus the non-myeloablative conditioning regimen was compared. The percentage of allo-HSCT recipients who achieved CR in the aprepitant group was 30.0% versus 9.1% for the control group (\( p = 0.091 \)), and the rates of CR for the non-myeloablative conditioning regimen were 61.5% and 40.0%, respectively (\( p = 0.147 \)) (Table 3).

**Risk Factors for non-CR**

In univariate analysis, nonprophylactic use of aprepitant (57.1% vs 31.3%, \( p = 0.027 \)), TBI (39.3% vs 9.4%, \( p = 0.003 \)), and the myeloablative conditioning regimen (60.7% vs 25.0%, \( p = 0.002 \)) were significantly associated with failure to achieve CR. On stepwise logistic regression with backward selection, the predictors significantly associated with failure to achieve CR were nonprophylactic use of aprepitant (odds ratio [OR] 2.92; 95% confidence interval [CI] 1.13–7.99; \( p = 0.031 \)) and myeloablative conditioning regimen (OR 3.92; 95% CI 1.45–10.31; \( p = 0.008 \)).

![Figure 1. Comparison of the daily and overall percentages of patients with complete response (A) and no vomiting (B) between aprepitant and control groups during the first day of conditioning therapy through 5 days after end of conditioning for each regimen. \( * p < 0.05 \); \( ** p < 0.01 \).](image-url)

| Conditioning Regimens | Complete response |
|-----------------------|------------------|
|                       | Control (n=42)   | Aprepitant (n=46) |
| Myeloablative regimens (%) |                  |                  |
| TBI/CY                | 1/13 (7.7)       | 2/12 (16.7)      |
| BU/CY                 | 0/4 (0)          | 1/2 (50.0)       |
| Flu/BU4               | 1/5 (20.0)       | 3/6 (50.0)       |
| Total                 | 2/22 (9.1)       | 6/20 (30.0)      | 0.001 |
| Nonmyeloablative regimens (%) |                |                  |
| Flu/Bu2               | 4/6 (66.7)       | 6/12 (50.0)      |
| Flu/CY                | 0/3 (0)          | 1/1 (100)        |
| Flu/MEL/TBI           | 4/11 (36.4)      | 9/13 (69.2)      |
| Total                 | 8/20 (40.0)      | 16/26 (61.5)     | 0.147 |

TBI = total body irradiation; CY = cyclophosphamide, BU = busulfan; Flu = fludarabine, MEL = melphalan.
conditioning regimens (OR 4.62; 95% CI 1.77–13.10, p=0.003).

Safety

Rates of abdominal pain were lower in the aprepitant group than in the control group (Table 4). The rates for other frequently observed ADEs, such as malaise, diarrhea, headache, skin rash and flushing, and insomnia, were not significantly different between groups. These ADEs were rated as grade 2 or lower and were considered tolerable. Aprepitant was discontinued in one patient each due to ADEs with grade 2 skin rash, grade 1 insomnia, and grade 2 dysuria; however, no patients were excluded from the present study due to severe toxicities.

Events Associated with HSCT and Clinical Outcomes

The incidence and severity of oral mucositis were not significantly different in the aprepitant and control groups (all grades 15.2% vs 14.3%, p=1.000; grade 2 6.5% vs 4.8%, p=1.000). Neutrophil recovery was obtained promptly in both groups (median 18 days in the aprepitant group and 17 days in the control group, p=0.461). There was no significant difference in the time to achieve platelet engraftment (median 32 vs 32 days, p=0.818). There were no significant differences in the incidence and severity of acute GVHD (all grades 63.0% vs 54.8%, p=0.517; grades 2–3: 34.8% vs 35.7%), bloodstream infection (26.1% vs 23.8%, p=1.000), viral infection (73.9% vs 66.7%, p=0.491), or unexpected fever (43.5% vs 54.8%, p=0.393) between the two groups. In addition, there was no significant difference in OS at 1 year between the two groups (Figure 2).

Interaction Between Aprepitant and Blood Concentration of Tacrolimus or Cyclosporine A

There were no significant differences in the mean concentration of cyclosporine A in the aprepitant and control groups on day 0 (164.1 ± 79.7 [ng/ml] vs 157.7 ± 57.4 [ng/mL], p=0.789), day 1 (157.1 ± 33.7 vs 170.9 ± 60.7, p=0.432), or day 2 (198.2 ± 45.8 vs 178.4 ± 46.2, p=0.549) (Table 5). Similarly, the mean concentrations of tacrolimus in the aprepitant and control groups were not significantly different on day 0 (13.3 ± 5.6 vs 12.8 ± 5.3, p=0.786), day 1 (13.8 ± 6.4 vs 13.1 ± 3.6, p=0.673), or day 2 (14.3 ± 4.7 vs 14.0 ± 3.4, p=0.799) (Table 5).

Discussion

This study retrospectively evaluated the efficacy and safety of aprepitant in allo-HSCT recipients. No increase in the incidence and severity of ADEs, such as malaise, diarrhea, and headache, occurred in patients who received aprepitant compared with the control group. In addition, there were no significant differences in the incidence of acute GVHD, infectious complications, engraftment, or 1-year OS between the aprepitant and control groups. In contrast, aprepitant dramatically improved the incidence and severity of vomiting and nausea, indicating that aprepitant in addition to standard

| Adverse Drug Events       | Control (n=42)a | Aprepitant (n=46)b | p Value |
|---------------------------|----------------|-------------------|---------|
| Malaise (%)               | 42 (100)       | 43 (94.1)         | 0.243   |
| Diarrhea (%)              | 40 (87.5)      | 37 (80.0)         | 0.052   |
| Headache (%)              | 22 (46.9)      | 26 (55.9)         | 0.831   |
| Skin rash and flushing (%)| 17 (37.5)      | 16 (33.3)         | 0.662   |
| Insomnia (%)              | 20 (43.8)      | 14 (29.4)         | 0.126   |
| Constipation (%)          | 1 (3.1)        | 7 (14.7)          | 0.060   |
| Abdominal pain (%)        | 12 (25.0)      | 4 (8.8)           | 0.025   |
| Hiccups (%)               | 7 (15.6)       | 4 (8.8)           | 0.339   |
| Tremors (%)               | 3 (6.3)        | 3 (5.9)           | 1.000   |
| Hypersensitivity (%)      | 0 (0)          | 3 (5.9)           | 0.243   |
| Dizziness (%)             | 1 (3.1)        | 1 (2.9)           | 1.000   |
| Dysuria (%)               | 0 (0)          | 1 (2.9)           | 1.000   |
| Back pain (%)             | 4 (9.4)        | 0 (0)             | 0.048   |
| Muscle pain (%)           | 3 (6.3)        | 0 (0)             | 0.105   |

aPatients in the control group received granisetron alone as an antiemetic.
bPatients in the aprepitant group received aprepitant and granisetron as antiemetics.
Table 5. Blood Concentrations of Calcineurin Inhibitors

|               | Control (n=42) | Aprepitant (n=46) | p Value |
|---------------|---------------|------------------|---------|
| Cyclosporine A|               |                  |         |
| Day 0         | 157.7 ± 57.4  | 164.1 ± 79.7     | 0.789   |
| Day 1         | 170.9 ± 60.7  | 157.1 ± 33.7     | 0.432   |
| Day 2         | 178.4 ± 46.2  | 198.2 ± 45.8     | 0.549   |
| Tacrolimus    |               |                  |         |
| Day 0         | 12.8 ± 5.3    | 13.3 ± 5.6       | 0.786   |
| Day 1         | 13.1 ± 3.6    | 13.8 ± 6.4       | 0.673   |
| Day 2         | 14.0 ± 3.4    | 14.3 ± 4.7       | 0.799   |

Cyclosporine A and tacrolimus blood concentrations were compared on the day of hematopoietic stem cell transplantation (day 0) and the following 2 days. Calcineurin inhibitor concentrations were expressed as the mean ± SD.

Patients in the control group received granisetron alone as an antiemetic.

Patients in the aprepitant group received aprepitant and granisetron as antiemetics.

antiemetic therapies may be a promising antiemetic therapy in the setting of allo-HSCT.

Because aprepitant moderately inhibits CYP 3A4, drug–drug interactions may occur when aprepitant is administered in combination with anticancer drugs including cyclophosphamide, as well as cyclosporine A or tacrolimus. One study reported that the area under the curve of 4-hydroxy cyclophosphamide decreased by 5% in the presence of aprepitant in patients who underwent cyclophosphamide therapy (1.5 g/m²/day×4 days) for autologous peripheral blood stem cells mobilization, although this was not clinically significant. Another study reported that aprepitant did not alter the pharmacokinetic profile of melphalan. Recently, we reported that the addition of aprepitant to granisetron improved antiemetic control without influencing ADEs in patients with hematologic malignancies receiving multiday standard-dose chemotherapy. And the regimens in that study were including ESHAP (etoposide + cisplatin + cytarabine + methylprednisolone) therapy for malignant lymphoma, induction therapy consisted of cytarabine and idarubicin for acute myeloblastic leukemia (AML), high-dose cytarabine therapy for AML, induction (cyclophosphamide + daunorubicin + vincristine + prednisolone) therapy for acute lymphocytic leukemia, hyper CVAD (cyclophosphamide + vincristine + doxorubicin + dexamethasone) therapy for malignant lymphoma, or CHOP-V-MMV (cyclophosphamide + vincristine + doxorubicin + etoposide + prednisolone + mitoxantrone + ranimustine + vindesine) therapy for adult T-cell leukemia/lymphoma. Another study reported that the addition of aprepitant to tacrolimus treatment resulted in modest but clinically insignificant increases in tacrolimus blood concentrations. Similarly, we found that aprepitant did not affect the blood concentration of cyclosporine A or tacrolimus and did not exacerbate ADEs during the transplantation period. Based on these results, we believe that aprepitant may be safely added to conditioning regimens for allo-HSCT.

The percentage of patients with CR and with no vomiting was significantly higher in the aprepitant group than the control group. Prophylactic use of aprepitant significantly increased the CR rate by 24% (Figure 1). Although methodologic differences preclude direct comparisons between antiemetic regimens with and without aprepitant, similar improvements in the CR rate were reported in a recent clinical trial. A prospective, placebo-controlled, randomized phase 3 trial evaluated the efficacy of aprepitant in combination with ondansetron and dexamethasone in patients treated with ablative conditioning regimens for both auto- and allo-HSCT. The CR rate increased by 16% in the aprepitant group, whereas other outcomes including safety, progression-free survival, and OS were similar in both groups. In that study, approximately half of the patients were allo-HSCT recipients. The levels of tacrolimus in allo-HSCT patients on the day of transplantation were not significantly different. No other subgroup analysis with a focus on allo-HSCT was conducted. Another study evaluated the pharmacokinetics of aprepitant, concurrent cyclophosphamide, and two major metabolites of cyclophosphamide in patients undergoing HSCT. Although the vast majority of patients underwent allo-HSCT, the effectiveness and safety of the addition of aprepitant to standard antiemetic therapy were not reported in that publication. A randomized double-blind pilot trial of aprepitant added to standard antiemetics during conditioning regimens for HSCT reported that aprepitant improved emesis prevention without significant changes in cyclophosphamide pharmacokinetics or increased toxicity. Another study administered aprepitant in combination with palonosetron and dexamethasone for patients receiving busulfan and cyclophosphamide therapy prior to allo-HSCT and found that this triple combination was more effective than historical control groups (dexamethasone and either ondansetron or palonosetron) in preventing CINV. In that study, constipation was similar between groups; no other outcome was evaluated. In the present study, we evaluated the...
efficacy and safety of aprepitant, as well as the influence of aprepitant on transplantation-related outcomes, in allo-HSCT recipients. Despite the shorter administration duration of aprepitant than in other studies,\(^4\) multivariate analysis clearly revealed that prophylactic use of aprepitant was significantly associated with CR. Therefore, prophylactic use of aprepitant can improve the control of CINV in patients treated with high-dose chemotherapy followed by allo-HSCT.

In a subgroup analysis, the CR rate in the aprepitant group who received the TBI/CY regimen was only 17% (2 of 12) (Table 3). This insufficient control of nausea and vomiting may depend on the duration of aprepitant administration. In fact, 8 of 12 patients (67%) in the aprepitant group who received the TBI/CY regimen already experienced vomiting on day \(-4\) (data not shown). Because aprepitant is not approved for the prevention of radiation-induced nausea and vomiting in Japan\(^26\), administration of aprepitant started after TBI (from day \(-3\) to \(-1\)) for patients receiving the TBI/CY regimen (Table 1). In animal experiments\(^38\), a combination of an NK\(_3\) receptor antagonist, a 5-HT\(_3\) receptor antagonist, and dexamethasone completely inhibited kaolin intake, which is an index of nausea and vomiting in mice, induced by 9 Gy of TBI. In a randomized controlled trial\(^20\), aprepitant was started on the first day of chemotherapy or TBI and showed benefit in patients receiving high-dose chemotherapy with or without TBI. Taken together, prophylactic use of aprepitant for TBI is likely to improve the control of radiation-induced nausea and vomiting. Moreover, recent American Society of Clinical Oncology guidelines recommend dexamethasone in combination with a 5-HT\(_3\) receptor antagonist in patients receiving TBI.\(^2\)

Therefore, the addition of dexamethasone is also likely to improve the control of nausea and vomiting in those patients.

Limitations of this study include the retrospective study design, lack of evaluation of specific pharmacokinetic parameters for each chemotherapy agent, and no evaluation of aprepitant for radiation-induced nausea and vomiting with the TBI regimen. Therefore, this study could not confirm that aprepitant affected clinical outcomes of these anticancer drugs and could not confirm the efficacy of aprepitant prior to TBI. Although current guidelines of antiemetic therapy\(^2,\)\(^3,\)\(^4\) recommend dexamethasone in combination with a 5-HT\(_3\) receptor antagonist for conditioning regimens prior to HSCT, no patient received dexamethasone for CINV prophylaxis in this study. The dose of granisetron was also different in other clinical studies\(^9,\)\(^12\) because the approved dose of granisetron is up to 6 mg/day in Japan.\(^39,\)\(^40\) Thus our findings cannot be directly applied to other institutions. Palonosetron, a long-acting 5-HT\(_3\) receptor antagonist, improves the control of CINV in combination with dexamethasone in patients receiving high-dose chemotherapy prior to HSCT.\(^41,\)\(^42\)

However, because only a single dose of palonosetron is approved in Japan, we used granisetron rather than palonosetron in those patients receiving multiday chemotherapy. Finally, the small sample size in our subgroup analysis precluded definitive conclusions about the antiemetic efficacy of aprepitant.

**Conclusion**

The addition of aprepitant to granisetron in conditioning regimens for allo-HSCT increased the antiemetic effect without influencing toxicity and therapeutic outcomes in our patient population. Prospective studies are warranted to further define the role of aprepitant as part of the antiemetic regimen in patients undergoing allo-HSCT.

**Acknowledgment**

The authors would like to thank Dr. Joseph S. Bulbulo, Department of Pharmacy Services, Oregon Health & Science University, for his review of the manuscript. This study was supported by MEXT KAKENHI Grant Number 24928027.

**References**

1. Hesketh PJ. Chemotherapy-induced nausea and vomiting. N Engl J Med 2008;358:2482–94.
2. Basch E, Prestrud AA, Hesketh PJ, et al. Antiemetics: American Society of Clinical Oncology clinical practice guideline update. J Clin Oncol 2011;29:4189–98.
3. National Comprehensive Cancer Network (NCCN). NCCN Clinical Practice Guidelines in Oncology: Antiemesis V.1.2012. Available from http://www.nccn.org/professionals/physician_gls/pdf/antiemesis.pdf. Accessed August 31, 2012.
4. Einhorn LH, Grunberg SM, Rapoport B, et al. Antiemetic therapy for multiple-day chemotherapy and additional topics consisting of rescue antiemetics and high-dose chemotherapy with stem cell transplant: review and consensus statement. Support Care Cancer 2011;19(Suppl 1):S1–4.
5. Yen CC, Hsieh RK, Chiou TJ, et al. Navohan (tropisetron, ICS 205-930) and dexamethasone combination in the prevention of vomiting for patients receiving preconditioning high-dose chemotherapy before marrow transplantation. Jpn J Clin Oncol 1998;28:120–33.
6. Climent MA, Palau J, Ruiz A, et al. The antiemesis efficacy of granisetron plus dexamethasone, haloperidol and lorazepam in breast cancer patients treated with high-dose chemotherapy.
with peripheral blood stem-cell support. Support Care Cancer 1998;6:287–90.

7. Osowski CL, Dix SP, Lynn M, et al. An open-label dose comparison study of ondansetron for the prevention of emesis associated with chemotherapy prior to bone marrow transplantation. Support Care Cancer 1998;6:311–7.

8. Barbounis V, Koumakis G, Hatzichristou V, Vassilomanolakis M, Tsoussis S, Efremidis A. The anti-emesis efficacy of tropisetron plus dexamethasone in patients treated with high-dose chemotherapy and stem cell transplantation. Support Care Cancer 1999;2:79–83.

9. Abbott B, Ippoliti C, Hecth D, Bruton J, Whaley B, Champlin R. Granisetron (Kytril) plus dexamethasone for antiemesis control in bone marrow transplant patients receiving highly emetogenic chemotherapy with or without total body irradiation. Bone Marrow Transplant 2000;25:1279–83.

10. Ballen KK, Hesketh AM, Heyes C, et al. Prospective evaluation of antiemesis outcome following high-dose chemotherapy with hematopoietic stem cell support. Bone Marrow Transplant 2001;28:1061–6.

11. Matsuoka S, Okamoto S, Watanabe R, et al. Granisetron plus dexamethasone vs granisetron alone in the prevention of vomiting induced by conditioning for stem cell transplantation: a prospective randomized study. Int J Hematol 2003;77:86–90.

12. Walsh T, Morris AK, Holle LM, et al. Granisetron vs ondansetron for prevention of nausea and vomiting in hematopoietic stem cell transplant patients: results of a prospective, double-blind, randomized trial. Bone Marrow Transplant 2004;34:963–8.

13. Trigg ME, Inverso DM. Nausea and vomiting with high-dose chemotherapy and stem cell rescue therapy: a review of antiemesis regimens. Bone Marrow Transplant 2008;42:501–6.

14. de Wit R, Herrstedt J, Rapoport B, et al. Addition of the oral NK1 antagonist aprepitant to standard antiemetics improves control of chemotherapy-induced nausea and vomiting during multiple cycles of cisplatin-based chemotherapy. J Clin Oncol 2003;21:4105–11.

15. Poli-Bigelli S, Rodrigues-Pereira J, Carides AD, et al. Addition of the neurokinin 1 receptor antagonist aprepitant to standard antiemetic therapy improves control of chemotherapy-induced nausea and vomiting. Results from a randomized, double-blind, placebo-controlled trial in Latin America. Cancer 2003;97:3000–8.

16. Warr DG, Hesketh PJ, Gralla RJ, et al. Efficacy and tolerability of aprepitant for the prevention of chemotherapy-induced nausea and vomiting in patients with breast cancer after moderately emetogenic chemotherapy. J Clin Oncol 2005;23:2822–30.

17. Bubalo JS, Leis LF, Curtin PT, et al. A randomized, double-blind, pilot trial of aprepitant added to standard antiemetics during conditioning therapy for hematopoietic stem cell transplant (HSCT). J Clin Oncol 2007;25(18s):9112.

18. Paul B, Trovato JA, Thompson J, Badros AZ, Goloubeva O. Efficacy of aprepitant in patients receiving high-dose chemotherapy with hematopoietic stem cell support. J Oncol Pharm Pract 2010;16:45–51.

19. Jordan K, Jahn F, Jahn P, et al. The NK-1 receptor-antagonist aprepitant in high-dose (HD) chemotherapy (HD melphalan and HD T-ICE: paclitaxel, ifosfamide, carboplatin, etoposide): efficacy and safety of a triple antiemetics combination. Bone Marrow Transplant 2011;46:784–9.

20. Stiff PJ, Fox-Geiman MP, Kiley K, et al. Prevention of nausea and vomiting associated with stem cell transplantation: results of a prospective, randomized trial of aprepitant used with highly emetogenic preparative regimens. Biol Blood Marrow Transplant 2011;17:49–55.

21. Pielichowski W, Barzal J, Gawronska K, et al. A triple-drug combination to prevent nausea and vomiting following BEAM chemotherapy before autologous hematopoietic stem cell transplantation. Transplant Proc 2011;43:3107–10.

22. Copelan EA. Hematopoietic stem-cell transplantation. N Engl J Med 2006;354:1813–26.

23. Majumdar AK, McAcre JR, Panchbianco DL, et al. Effects of aprepitant on cytochrome P450 3A4 activity using midazolam as a probe. Clin Pharmacol Ther 2003;74:150–6.

24. Aapro MS, Walko CM. Aprepitant: drug–drug interactions in perspective. Ann Oncol 2010;21:2316–23.

25. Glotzbeker B, Duncan C, Aleya E 3rd, Campbell B, Soiffer R. Important drug interactions in hematopoietic stem cell transplantation: what every physician should know. Biol Blood Marrow Transplant 2012;18:989–1006.

26. Ono Pharmaceutical. EMEND (aprepitant) package insert. Osaka, Japan; 2012.

27. Bubalo JS, Cherafa G, McCune JS, Munar MY, Tse S, Maziärz R. Aprepitant pharmacokinetics and assessing the impact of aprepitant on cyclophosphamide metabolism in cancer patients undergoing hematopoietic stem cell transplantation. J Clin Pharmacol 2012;52:586–94.

28. Egerer G, Eisenlohr K, Gronkowski M, Burhenne J, Riedel KD, Mikus G. The NK receptor antagonist aprepitant does not alter the pharmacokinetics of high-dose melphalan chemotherapy in patients with multiple myeloma. Br J Clin Pharmacol 2010;70:903–7.

29. de Jonge ME, Huijtema AD, Holkamp MJ, et al. Aprepitant inhibits cyclophosphamide bioactivation and thiopeta metabolism. Cancer Chemother Pharmacol 2005;56:370–8.

30. Przepiorka D, Weisdorf D, Martin P, et al. 1994 Consensus conference on acute GVHD grading. Bone Marrow Transplant 1995;13:823–8.

31. Filippovich A, Weisdorf D, Pavletic S, et al. National Institutes of Health consensus development project on criteria for clinical trials in chronic graft-vs-host disease: I. Diagnosis and staging working group report. Biol Blood Marrow Transplant 2005;11:945–56.

32. Velasquez WS, McLaughlin P, Tucker S, et al. ESHAP-an effective chemotherapy regimen in refractory and relapsing lymphoma: a 4-year follow-up study. J Clin Oncol 1994;12:1169–76.

33. Ohtake S, Miyawaki S, Fujita H, et al. Randomized study of induction therapy comparing standard-dose idarubicin with high-dose daunorubicin in adult patients with previously untreated acute myeloid leukemia: JALSG AML201 Study. Blood 2011;117:2358–65.

34. Mayer RJ, Davis RB, Schiffer CA, et al. Intensive postremission chemotherapy in adults with acute myeloid leukemia. Cancer and Leukemia Group B. N Engl J Med 1994;331:896–903.

35. Uchida M, Ikuesu H, Kato K, et al. Efficacy and safety of aprepitant in patients with hematologic malignancies receiving multi-day chemotherapy. Ann Hematol Syst Pharm 2013;70:343–9.

36. Ibrahim RB, Abidi MH, Ayash LJ, et al. Effect of aprepitant on intravenous tacrolimus disposition in reduced intensity hematopoietic stem cell transplantation. J Oncol Pract 2008;14:113–21.

37. Pielichowski W, Gawronska K, Mlot B, et al. Triple drug combination in the prevention of nausea and vomiting following busulfan plus cyclophosphamide chemotherapy before allogeneic hematopoietic stem cell transplantation. J BUON 2011;16:541–6.

38. Yamamoto K, Nohara K, Furuya T, Yamatodani A. Ondansetron, dexamethasone and an NK1 antagonist block radiation sickness in mice. PharmacoBioChem Behav 2005;82:24–9.

39. Furue H, Oota K, Taguchi T, Niitani H. Clinical evaluation of granisetron against nausea and vomiting induced by anticycancer drugs (1) [in Japanese]. J Clin Ther Med 1990;5:49–61.

40. Chugai Pharmaceutical. Kytril (granisetron) package insert. Tokyo, Japan; 2011.

41. Musso M, Scalone R, Crescimanno A, et al. Palonosetron and dexamethasone for prevention of nausea and vomiting in patients receiving high-dose chemotherapy with auto-SCT. Bone Marrow Transplant 2010;45:123–7.

42. Giralt SA, Mangan KF, Maziärz RT, et al. Three palonosetron regimens to prevent CINV in myeloma patients receiving multiple-day high-dose melphalan and hematopoietic stem cell transplantation. Ann Oncol 2011;22:939–46.